NOT FOR DISTRIBUTION
Header cover image

Market Cap

HK$245.7m

Last Updated

2021/04/11 10:17 UTC

Data Sources

Company Financials

Executive Summary

China NT Pharma Group Company Limited, together with its subsidiaries, researches and develops, manufactures, sells, and distributes pharmaceutical products in the People’s Republic of China and internationally. More Details


Snowflake Analysis

Worrying balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has China NT Pharma Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1011 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: 1011's weekly volatility (11%) has been stable over the past year.


Market Performance


7 Day Return

-5.1%

1011

0.8%

HK Pharmaceuticals

-1.1%

HK Market


1 Year Return

-30.6%

1011

21.2%

HK Pharmaceuticals

28.6%

HK Market

Return vs Industry: 1011 underperformed the Hong Kong Pharmaceuticals industry which returned 20.9% over the past year.

Return vs Market: 1011 underperformed the Hong Kong Market which returned 29.2% over the past year.


Shareholder returns

1011IndustryMarket
7 Day-5.1%0.8%-1.1%
30 Day-5.8%0.7%-1.8%
90 Day11.2%10.0%3.4%
1 Year-30.6%-30.6%23.0%21.2%33.5%28.6%
3 Year-94.2%-94.3%-14.3%-19.1%4.0%-6.9%
5 Year-93.9%-94.1%79.2%62.4%48.7%23.7%

Long-Term Price Volatility Vs. Market

How volatile is China NT Pharma Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is China NT Pharma Group undervalued compared to its fair value and its price relative to the market?

12.48x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1011's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1011's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1011 is unprofitable, so we can't compare its PE Ratio to the HK Pharmaceuticals industry average.

PE vs Market: 1011 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1011's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1011 is overvalued based on its PB Ratio (12.5x) compared to the HK Pharmaceuticals industry average (1.3x).


Future Growth

How is China NT Pharma Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China NT Pharma Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has China NT Pharma Group performed over the past 5 years?

-51.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1011 is currently unprofitable.

Growing Profit Margin: 1011 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1011 is unprofitable, and losses have increased over the past 5 years at a rate of 51.6% per year.

Accelerating Growth: Unable to compare 1011's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1011 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).


Return on Equity

High ROE: 1011 has a negative Return on Equity (-853.04%), as it is currently unprofitable.


Financial Health

How is China NT Pharma Group's financial position?


Financial Position Analysis

Short Term Liabilities: 1011's short term assets (CN¥577.0M) do not cover its short term liabilities (CN¥1.2B).

Long Term Liabilities: 1011's short term assets (CN¥577.0M) exceed its long term liabilities (CN¥116.2M).


Debt to Equity History and Analysis

Debt Level: 1011's debt to equity ratio (3754.7%) is considered high.

Reducing Debt: 1011's debt to equity ratio has increased from 29.1% to 3754.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if 1011 has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 1011 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is China NT Pharma Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1011's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1011's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1011's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1011's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 1011 is not paying a notable dividend for the Hong Kong market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1011's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.5yrs

Average management tenure


CEO

David Ng (56 yo)

26.25yrs

Tenure

CN¥6,352,000

Compensation

Mr. Tit Ng, also known as David, has been the Chief Executive Officer, and Chairman of China NT Pharma Group Company Limited since 1995. He is a Co-Founder of NT Pharma Group Company Limited. Mr. Ng was ap...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD969.61K) is above average for companies of similar size in the Hong Kong market ($USD230.00K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 1011's management team is seasoned and experienced (5.5 years average tenure).


Board Members

Experienced Board: 1011's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

China NT Pharma Group Company Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: China NT Pharma Group Company Limited
  • Ticker: 1011
  • Exchange: SEHK
  • Founded: 1995
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$245.698m
  • Shares outstanding: 1.90b
  • Website: https://www.ntpharma.com

Number of Employees


Location

  • China NT Pharma Group Company Limited
  • S2 The Bund Finance Center
  • 11th Floor
  • Shanghai
  • 200010
  • China

Listings


Biography

China NT Pharma Group Company Limited, together with its subsidiaries, researches and develops, manufactures, sells, and distributes pharmaceutical products in the People’s Republic of China and internatio...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 10:17
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.